PP107-SUN: Glutamine and Total Parenteral Nutrition in Bone Narrow Transplant Patients

Herrera‐Martínez, Aura D.; García, González; Expósito, Manuela; Puerta, María José Molina; Jiménez, C; Continente, Alfonso Calañas; Jiménez, C.; Sánchez, Íñigo; Opazo, R. Bahamondes; M, Moreno Azcoíta

doi:10.1016/s0261-5614(14)50149-5

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(26,29) Monitoring of laboratory data indicating nutritional status as serum albumin and serum total protein are reliable indicators of visceral protein status. These parameters showed statistically significance differences between Gln and control groups in the present study which contradicted findings in Herrera-Martínez AD et al, (24) and Sornsuvit et al (7) . This may be due to the small sample size collected particularly in the later.…”

Section: Discussioncontrasting

confidence: 98%

“…(9) The mean length of hospital stay in the Gln group was significantly lower than the control group. This reduction in length of hospital stay matched reports from Sornsuvit et al (7) , Ziegler et al, (23) , Herrera-Martínez et al, (24) and Scheid et al, (25) .. Days of neutropenia are also affected by the use of G-CSF's in the appropriate dose. The observed effect of glutamine dipeptide on neutrophil recovery was not influenced by the use of G-CSF's in the present study.…”

Section: Discussionsupporting

confidence: 80%

See 1 more Smart Citation

Early Parenteral Supplementation with Glutamine Dipeptide for Acute Myeloid Leukaemia Patients Receiving High Dose Chemotherapy

Selim

El-Fattah

Darwish

et al. 2015

Journal of High Institute of Public Health

View full text Add to dashboard Cite

Background: Glutamine dipeptide (Gln) is one of conditionally essential amino acids that have a crucial role in cancer. Objectives: The aim of this study was to investigate the effects of early Gln supplementation in patients with acute myeloid leukemia (AML) receiving intensive chemotherapy, but without bone marrow transplant and regardless of receiving parenteral nutrition. Methods: A randomized control trial was carried out and included 46 AML patients who received high dose chemotherapy. Their ages ranged between 17-65 years. AML patients were randomly allocated as intervention group (Gln group; n=23) and control group (n=23). Gln group received intravenous supplementation with Gln (40 gm) from day 1 to day 5 of chemotherapy, while the patients in the control group received 40 gm per day of a standard amino acid mixture. Clinical end points included the body weight, body mass index, length of hospital stay, days of neutropenia, superoxide anion generation and length of neutropenic fever and serum albumin difference. White blood cells and absolute neutrophil count were done every second day till ANC reached >500µl then superoxide anion generation was measured. Results: Weight loss, length of hospital stay, the mean days of neutropenia and neutropenic fever were significantly lower in the Gln group, whereas the mean superoxide anion generation was found higher comparing to the control group (50 ng/L vs 43ng/L respectively). Complications other than febrile neutropenia were significantly less common in Gln group. Gln supplementation has resulted in significant improvement in serum total protein and serum albumin. Conclusion: This trial suggested that early Gln supplementation regardless receiving parenteral nutrition enhances neutrophil function, maintains nutritional status and decreases hospital stay.

show abstract